Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma

Simple Summary Diffuse midline glioma is a malignant brain tumor with no effective treatment. These tumors often harbor a Histone H3 K27M mutation, associated with a more aggressive clinical course and poorer response to treatment. Standard-of-care treatment is radiation therapy, but disease typically recurs or progresses despite treatment and there is a paucity of the literature specific to the features and outcomes of recurrent disease. Given this, our group sought to explore what factors may be associated with disease progression and clinical outcomes to guide disease management and prognosis. Through a multicenter retrospective analysis of clinical data from patients with recurrent midline glioma and H3 K27M-mutant diffuse glioma, we identified features associated with poorer overall survival following progression following frontline therapy. Taken together, these data provide insight into tumor biology and clinical outcomes, potentially informing future clinical trials.